Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2021 | Myeloma: BCMA loss as an escape mechanism

B-cell maturation antigen (BCMA) has become a widely used therapeutic target in multiple myeloma, with three major forms of treatment including antibody–drug conjugates (ADCs), bispecific T-cell engagers (BITEs), and chimeric antigen receptor (CAR) T-cell therapies. In this video, Mehmet Samur, PhD, Dana-Farber Cancer Institute, Boston, MA, talks on BCMA loss as an escape mechanism. This interview took place during the 2nd Immune Effector Cell Therapy in MM Workshop in Boston, MA.